ABSTRACT
INTRODUCTION
For hPSCs (H9-ESCs/EP1-iPSCs), 15,000 cells were plated on each well of a Matrigel-coated 96-143 well dish. After 24 hrs of recovery, cells were treated with the indicated drugs and dissociated with Accutase
144
(Millipore-Sigma) and quenched with mTeSR media (STEMCELL Technologies) containing blebbistatin 145 (Sigma), followed by centrifugation at 300Xg for 5min to pellet the cells. Mitochondrial content for each 146 sample was measured as explained above.
148
Mitochondrial DNA Quantification by Flow cytometry. Flow cytometry-based measurements were done 149 using mitochondria specific dye, mito tracker deep red (MTDR, Molecular probes) using cell sorter SH800
150
(Sony) on analyzer mode. 10,000-20,000 cells were analyzed at the FL-4 channel (far-red) to measure 151 MTDR intensity. For 3 hr CCCP treatments (Fig. 1G, I ), cells were labelled first while for 24 hrs treatments, 152 cells were labelled after the drug treatments with media containing 10nM MTDR for 15min at 37 0 C. Cells
153
were dissociated and centrifuged as explained in the qPCR method followed by suspension in media without 7 Cell Viability and Apoptosis Measurements. Cell viability and apoptosis were measured using ApoTox-400nm (viability) and 482nm (cytotoxicity) channels, and apoptosis was measured by luminescence-based caspase-3/7 activity. hPSCs (10,000/well) and RGCs (15,000/well) were plated on each well of Matrigel-161 coated 96well dish in mTeSR containing blebbistatin and N2B27 media respectively. After one day (hPSCs) 162 and three days (RGCs) of recovery, cells were treated with the indicated drugs for 24 hrs and analyzed for 163 cell viability and apoptosis.
165
Image Acquisition to Show Cell Viability. Images were acquired after indicated treatments using EVOS
166
FL Imaging System (ThermoFisher Scientific).
168
Lysosome/acidic Vesicles Inhibition Assay. 20,000 H9-RGCs were plated and grown on Matrigel-coated glass-bottom dish (MatTek) in N2B27 media for three days in the 37 0 C normoxia incubator (5% CO2).
170
After 24 hrs of treatment with the endo-lysosomal inhibitors Baf or HCQ, media was replaced with 100µl
171
of media containing pH sensitive pHrodo-green conjugated dextran solution (ThermoFisher Scientific) (100 Immunofluorescence and Imaging. For measuring ubiquitination level, 20,000 purified RGCs were plated 181 on matrigel-coated glass-bottom dishes (MatTek) for three days followed by 24 hrs of treatment with the 182 indicated drugs. Cells were fixed with 4% paraformaldehyde in PBS for 15min at 37 0 C followed by 1 hr of 183 blocking at room temperature with blocking solution (PBS with 5% donkey serum and 0.2%Triton X-100).
184
Samples were incubated with primary antibody against ubiquitin (Rabbit-anti-ubiquitin 
191
(Mouse-anti-VGLUT, SYSY, 1:2500 dilution) and VGAT (Rabbit-anti-VGAT, SYSY, 1:500 dilution).
192
Confocal images were acquired using LSM 710 (Zeiss) as done for pHrodo-Green, but without the live set-
193
up.
195
Statistical Analysis. Statistical comparisons between two data sets were done with the Student's t-test.
196
One-way ANOVA tests (Table1) were performed for analysis containing three or more independent groups.
198

RESULTS
199
RGCs are More Efficient in Degrading Damaged Mitochondria than Their Precursor Stem Cells.
200
To investigate mitochondrial degradation in both human RGCs and in their stem cell origin, we 201 used a CRISPR/Cas9 mediated genetically engineered human embryonic stem cell (hESC-H9) reporter line
202
with a P2A-tdTomato-P2A-Thy1.2 construct introduced into the endogenous RGC-specific POU4F2
203
(BRN3B) locus [33] . Small molecule-based differentiation followed by immunopurification of Thy1. lead to a buildup of CCCP-induced damaged mitochondria, hence there would be an increase of cell death.
of H9-RGCs (Fig. 1D) . As with the H9-ESCs, CCCP treatment did not result in RGC cell death at 24 hrs
217
( Fig. 1E, F ; there was a small decrease in cell viability, but it was not statistically significant). These results
218
suggest that RGCs are may be more efficient in degrading damaged mitochondria than their precursor stem 219 cells.
220
With the unexpected result of no change in mitochondrial content with CCCP and yet no cell death
221
for H9-ESCs, we next asked whether ESCs might be clearing up damaged mitochondria while 222 simultaneously synthesizing more mitochondria to keep up with their metabolic needs for rapid cell not be detected, and hence will not mask possible degradation of pre-existing damaged mitochondria. 
256
CCCP treatment showed mitochondrial degradation in hPSCs (Fig. 1H, I ). Our inability to detect an increase 257 in mitochondria levels upon endo-lysosomal inhibition may suggest the existence of alternative pathway in 
272
OA result, we observed increased mitochondrial levels in H9-ESCs treated with CsA ( Fig. 2D , E).
273
Presumably because inhibition of damaged mitochondrial degradation can be toxic, CsA treatment also 274 caused increased cell death and activation of apoptosis ( Fig. 2F , G).
275
To test whether H9-RGCs degrade damaged mitochondria via endo-lysosomes, we blocked endo-
276
lysosomal activity with Baf and HCQ. HCQ (with and without CCCP), but not Baf, increased mitochondrial 277 content ( Fig. 2H ), indicating that HCQ is a more potent inhibitor of mitophagy in H9-RGCs than in hESCs.
278
As expected, presumably due to its inhibition of mitochondrial clearance, HCQ caused hRGC death and 279 apoptosis ( Fig. 2I , J). Although we did not observe increased levels of mitochondria with Baf treatment
280
( Fig. 2H ), we did observe increased H9-RGC apoptosis and cell death ( 
292
With the apparent difference between hESCs and hRGCs in choosing endo-lysosomal pathway and the
293
potential involvement of UPS in neurodegenerative diseases [51] , led us to ask the role of UPS for 294 mitochondrial clearance and neuro-protection in hRGCs and for the origin stem cells.
296
The UPS is Required for Mitochondrial Degradation and Cell Survival for hPSCs but not for 297 hRGCs.
298
As an alternative to the endo-lysosomal pathway, the proteasomal (UPS) pathway is the other 299 major cellular quality control pathway for the protein and organelle homeostasis [52] . We next 300 investigated the role of UPS in mitochondrial clearance by using the drug bortezomib to inhibit the 301 proteasome's 20S core particle [53] . Unexpectedly, we found that inhibiting proteasome in H9-ESCs 302 increased mitochondrial levels in a dose dependent manner (Fig. 3A, B ). As accumulation of damaged 303 mitochondria could lead to cellular toxicity, we further observed cell death and activation of the apoptotic 304 pathway in H9-ESCs with bortezomib treatment (Fig. 3C-E 328 also did not induce cell death or apoptosis in H9-RGCs (Fig. 3M-O) .
329
These results suggest a switch in the mitochondrial degradation pathways from the proteasome to 330 the endo-lysosomal pathway during human RGC differentiation, making the lysosomal-autophagy pathway 331 a potential therapeutic target for improving mitochondrial health and therefore hRGC survival in glaucoma
332
and in other forms of optic neuropathy patients. While these findings could be important for improving
333
hRGC health, we were additionally interested to see if these phenomena are specific for hRGCs or also true Inhibition.
339
To study the role of proteasomal and endo-lysosomal pathways for cortical neuron survival, we 340 differentiated cortical neurons from human stem cells (H1-ESCs) following published methods [57] .
341
Cultured human cortical neurons were tested and shown to be positive for expression of the mature neuronal 342 marker microtubule-associated protein 2 (MAP2), inhibitory marker vesicular GABA transporter (VGAT),
343
and excitatory marker vesicular glutamate transporter (VGLUT) (Fig. 4A) . To test the effect of endo-
344
lysosomal inhibition, cells were treated with HCQ. Similar to hRGCs, we observed significant cell death
345
and corresponding activation of apoptosis (Fig. 4B, C) , suggesting endo-lysosomal pathway is important
346
for cellular homeostasis in cortical neurons.
347
Next, we tested the effect of proteasomal inhibition by treating cortical neurons with the proteasome 348 inhibitor bortezomib. Interestingly, like hRGCs, proteasome inhibition did not cause cell death for human 349 cortical neurons (Fig. 4D, E) .
350
Taking together, our data suggest endo-lysosomal pathway may be the predominant pathway for 
Table 1
One-way ANOVA test for group of data containing three or more data sets Fig. 1A 1.3226E-05 Fig. 1B 0.36823588 Fig. 1D 0.00696819 Fig. 1E 0.27528422 Fig. 1J 6.288E-07 Fig. 1K 1.6562E-05 Fig. 2A 0.00333067 Fig. 2B 1.6741E-08 Fig. 2C 2.4542E-06 Fig. 2H 0.00193593 Fig. 2I 1.6819E-07 Fig. 2J 6.8186E-05 Fig. 3A 0.00080816 Fig. 3B 0.03867105 Fig. 3D 2.2998E-05 Fig. 3E 3.6587E-05 Fig. 3F 0.29285313 Fig. 3H 0.24560869 Fig. 3I 5.9384E-08 Fig. 3L 9.6407E-05 Fig. 3N 0.00954914 Fig. 3O 0.0737521 Fig. 4B 0.2133412 Fig. 4C 0.06621655 Fig. 4D 0.36246771 Fig. 4E 5.8274E-05 Fig. S4A 3.0732E-16 
Fig p value
